January 28, 2021
Monday, January 11, 2016
朱庇特,Fla. – Charleston Laboratories, Inc., a specialty pharmaceutical company, will expand its operations in Palm Beach County and create 25 jobs this year. Charleston Laboratories will also make a capital investment of $4 million into the community.
Governor Scott said, “We are excited to announce the creation of 25 new jobs for families in Jupiter today. Florida job creators like Charleston Laboratories have created more than one million jobs across our state in only five years, and in order to continue this growth, we will remain focused on our two objectives for this Legislative session: cutting $1 billion in taxes and creating the new $250 million Florida Enterprise Fund.”
查尔斯顿实验室公司总裁兼首席执行官保罗·博斯说:“我们很荣幸棕榈滩商业发展委员会和朱庇特镇认定查尔斯顿实验室拥有QTI计划的关键品质。佛罗里达州非常适合查尔斯顿总部,因为该州拥有丰富的人才,并且有能力凭借其充满活力的经济环境吸引其他地区的顶尖人才。我们期待成为社区的积极领导者,同时推动全球制药行业的创新。”
The expansion was made possible through partnerships between Enterprise Florida, the Florida Department of Economic Opportunity, the Business Development Board of Palm Beach County and the Town of Jupiter.
佛罗里达企业总裁兼首席执行官比尔·约翰逊说:“查尔斯顿实验室在棕榈滩的扩张对南佛罗里达来说是个好消息。通过创造额外的25个新工作岗位,他们在一个重要行业创造了机会,并支撑了棕榈滩县已经蓬勃发展的经济。随着佛罗里达成为全球商业目的地,我期待着他们继续取得成功。”
DEO Executive Director Cissy Proctor said, “The expansion of Charleston Laboratories shows Florida’s business community is continuing to diversify. The state’s focus on creating and retaining STEM-related jobs is great news for families in Palm Beach County and across Florida.”
“Charleston Laboratories is an example of the types of life sciences companies that continue to flourish in Palm Beach County,” said Kelly Smallridge, President and CEO of the Business Development Board of Palm Beach County. “It’s impressive that this company creates cutting edge, industry-changing products in our backyard and improves the quality of life for individuals across the globe.”
“We are excited to welcome Charleston Labs to the Jupiter Community,” said Mayor Karen Golonka. “Jupiter is happy to continue the trend of adding companies to its bioscience community with real commercialization and market opportunities that not only bring additional jobs and economic growth, but also have the potential to make a difference in people’s lives.”
***
查尔斯顿实验室, Inc.is a privately held, specialty pharmaceutical company focused on the research and development of novel pain products that prevent the burdensome side effects related to opioid analgesics and other products. The Company recently announced a strategic collaboration with Daiichi Sankyo, Inc. for the development and U.S. commercialization of Charleston Laboratories’ novel hydrocodone products, including CL-108, being studied for the treatment of moderate to severe pain while preventing or reducing Opioid-Induced Nausea and Vomiting (OINV). Charleston’s product pipeline currently seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV). Charleston Laboratories intends to enter into other discovery and commercialization alliances with partners motivated to introduce novel pain therapies that prevent the burdensome side effects related to opioid analgesics and other products. For more information, please visitwww.charlestonlabs.com.
###